71 results about "Signal pathway" patented technology

This invention relates to the field of cosmetic compositions, and more specifically to a synergistic anti-aging composition involving energy metabolism and autophagy, its preparation method, and its application. The composition comprises sea buckthorn fruit extract, trehalose, and a cosmetically acceptable polyol carrier. This invention pioneers a betaine-trehalose-NADES extraction system, achieving low-temperature, high-efficiency extraction while preserving the heat-sensitive active ingredients of sea buckthorn. Trehalose possesses both extraction and autophagy activation effects. A selective separation strategy achieves a balance between efficacy, compliance, and process simplicity. The green, circular process reduces costs and is environmentally friendly. Through the synergistic effect of sea buckthorn fruit extract and trehalose, the composition enhances mitochondrial membrane potential, increases ATP production, inhibits excessive activation of the mTOR pathway, and promotes LC3-II conversion, thus synergistically combating skin aging from multiple targets including cellular energy metabolism, signaling pathways, and autophagy.

The application discloses application of PGD2 in promoting rumen development of young ruminants, and application of PGD2 in young ruminants promotes proliferation and differentiation of rumen wall cells, and further promotes rumen development and improves the digestive and absorptive capacity of the rumen. 2+ It is found that PGD2 can promote rumen development by activating Ca signal pathways, promoting expression of CAMK2A protein, promoting cell cycle progression, promoting rumen development, and ensuring animal health. Therefore, PGD2 can be used for preparing a medicine for promoting rumen development of young ruminants.

The application relates to the application of lycorine hydrochloride in the preparation of a medicine for inhibiting the proliferation of a neointimal in a blood vessel. Lycorine hydrochloride has the effect of inhibiting the proliferation of a neointimal in a blood vessel, and the effect is mainly realized by inhibiting the proliferation and migration of vascular smooth muscle cells. In the body, the results show that lycorine hydrochloride can significantly inhibit the intimal proliferation caused by left common carotid artery ligation, and in vitro experiments prove that lycorine hydrochloride can intervene in the proliferation, migration and phenotype transformation of VSMCs induced by PDGF-BB. Lycorine hydrochloride inhibits the proliferation, migration and phenotype transformation of VSMCs induced by PDGF-BB, and the proliferation of a neointimal in a blood vessel through a MAPKs signal path. The application provides data for preparing lycorine hydrochloride into a medicine for inhibiting the proliferation of a neointimal in a blood vessel, and is expected to be applied to the prevention and treatment of complications after percutaneous coronary intervention, such as restenosis or in-stent thrombosis, and can become a potential medicine for intervening in restenosis.

The application is suitable for the field of biological medicine technology, and provides a siRNA-PSMA conjugate targeting a LEPR gene, a preparation method and application thereof. The siRNA-PSMA conjugate realizes specific targeted delivery of CRPC cells through a PSMA inhibitor target head, effectively reduces off-target toxicity, combines with a high-interference-efficiency M3 modified LEPR siRNA screened, can efficiently silence LEPR gene expression, block a leptin-LEPR signal pathway, and then inhibit CRPC cell proliferation, invasion and drug resistance related biological functions; the preparation process is stable and controllable, the purity of the finished product after purification can reach more than 95%, meets the quality requirements of drug development, and the activity verification method has strong specificity and reliable results, fills the blank of CRPC targeted therapy drugs in the prior art, provides a new precise targeting strategy for CRPC treatment, and has important clinical application value and broad conversion prospect.

A pyrrolopyrimidine or pyrrolopyridine derivative and its medical use. Specifically, the compound has the structure shown in formula I, has good inhibitory effect on focal adhesion kinase (FAK), and can inhibit its related signal pathways, and can be prepared for treating or preventing diseases related to cancer, pulmonary arterial hypertension, pathological angiogenesis, etc., and can be particularly used for treating diseases caused by excessive or abnormal cell proliferation, such as tumors or cancers.

The application discloses application of Pemigatinib or a salt thereof in preparation of a medicine, and the compound is used for treating seborrheic keratosis, preferably seborrheic keratosis related to abnormal activation of a fibroblast growth factor receptor (FGFR) signal pathway, but is not limited to the above mechanism, and specifically, the medicine can inhibit or improve skin hyperplasia and hyperkeratosis lesions driven by FGFR3 gene activating mutation.

This invention discloses a coumarin compound and its uses, belonging to the field of chemical and pharmaceutical technology. This invention provides coumarin compounds represented by Formula I, particularly some specific coumarin compounds. These compounds and their compositions can inhibit the MEK or Ras-MAPK signaling pathway, providing a new approach for treating diseases related to the MEK or Ras-MAPK signaling pathway.

The application discloses application of an inhibitor targeting CCL28 in treatment of visceral pain. The application firstly proves that CCL28 is significantly up-regulated in spinal cord dorsal horn neurons of a mouse model of visceral pain, and establishes CCL28 as a new target for treatment of visceral pain. On this basis, the application designs and screens a high-efficiency and specific siRNA sequence targeting CCL28, the siRNA can be delivered to the spinal cord locally through intrathecal injection, specifically silences CCL28 gene expression, inhibits activation of a downstream ERK signal pathway, thereby significantly alleviating visceral pain, and has no obvious off-target effect. The application provides a complete technical scheme from target discovery to drug intervention, provides a new strategy and a drug candidate molecule for treatment of visceral pain, and has a good clinical application prospect.

The application discloses an induction method for directional differentiation of neural stem cells into dopaminergic neurons, comprising the following steps: S1, activation and adhesion of NSCs; S2, directional induction of midbrain precursor cells; S3, directional induction of dopaminergic neurons; and S4, synaptic function maturation induction. The induction method for directional differentiation of neural stem cells into dopaminergic neurons can significantly improve the directional efficiency and lineage specificity of the midbrain precursor cells: by adding salvianolic acid B and icariin, and in cooperation with SHH, FGF8 and other induction factors, the midbrain lineage-specific signal pathway can be efficiently activated, the positive rate of the midbrain precursor cell marker LMX1A is increased to more than 76%, which is far better than 49% of the existing system, and abnormal differentiation of non-midbrain lineages is effectively inhibited.

The application discloses an application of lactobacillus reuteri BNCC186563 in prevention and improvement of related diseases caused by high-fat diet and belongs to the technical field of microorganisms. It is found that the lactobacillus reuteri BNCC186563 can synergistically activate a PPAR alpha signal pathway and remodel a glycerophospholipid metabolism network, and the lactobacillus reuteri BNCC186563 can be used as a potential medicine, health care product and functional food for preventing and improving related diseases caused by high-fat diet, such as obesity, impaired glucose tolerance, insulin resistance, abnormal lipid metabolism, liver lipid accumulation, liver damage, inflammation and hyperlipidemia.

The application relates to the field of biological medicine, and particularly relates to application of kaempferol-3-O-acacia di-saccharide-7-O-rhamnose glycoside in preparation of a medicine for preventing and / or treating diseases related to glycolipid metabolism disorder. The compound or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof can be used for treating diseases such as type 2 diabetes, insulin resistance, hyperglycemia, hyperlipidemia and non-alcoholic fatty liver disease. The compound can significantly reduce intracellular glucose, triglyceride and total cholesterol levels, and can play a role by activating an AKT signal pathway, so as to improve glycolipid metabolism disorder and has potential clinical application value.

This invention provides an application of type I interferon signaling pathway inhibitors in the preparation of drugs for treating age-related cataracts. By inhibiting type I interferon receptors, it can precisely intervene in the aging mechanism of lens epithelial cells, block the transmission of aging signals, and directly improve lens transparency, exhibiting higher therapeutic efficacy and targeting. The use of IFNAR inhibitors can effectively reverse the aging phenotype caused by STEAP3 deficiency, restore the proliferative capacity of lens epithelial cells, thereby maintaining lens transparency, significantly reducing surgical risks, and providing patients with an early intervention opportunity, delaying the onset and progression of cataracts. IFNAR inhibitors, through precise intervention in specific signaling pathways, have more significant therapeutic effects, and due to their targeting, have fewer side effects and are safer. They can not only improve existing cataracts but also play a preventive and delaying role in the early stages of cataracts. For patients with mild cataracts, the use of type I interferon receptor inhibitors can avoid premature surgical treatment, reducing patient dependence on surgery and also reducing the costs and risks associated with surgery.

The application belongs to the technical field of biological medicine, and particularly relates to an application of an expression agonist of lncRNA Morrbid in preparation of a drug for delaying heart failure and a pharmaceutical composition. The application first confirms a protective effect of lncRNA Morrbid in heart failure, proves that the lncRNA can significantly inhibit activation of myocardial fibroblasts and collagen deposition, reveals that the lncRNA is involved in regulation of key fibrosis and inflammatory signal pathways, and provides a new molecular intervention target for heart failure.

The present application relates to a kind of compositions for regulating autophagy of eukaryotic cell, improving mitochondrial dysfunction and its preparation method and application.It includes the following weight parts of raw materials: 10-30 parts of broccoli powder, 10-30 parts of wheat germ microcapsule powder, 20-40 parts of raspberry extract, 20-40 parts of banana powder, 2-6 parts of leucine, 0.1-1 parts of pyrroloquinoline quinone disodium salt.The present application also provides the preparation method of broccoli powder, wheat germ microcapsule powder, raspberry extract and banana powder, and the use of the composition.The composition combines the efficacy of the above 6 ingredients, reasonable compatibility, safe and effective, various components activate mitochondria through regulating protein, PINK1 / Parkin-dependent pathway and PINK1 / Parkin-independent pathway;At the same time, by activating PGC-1 alpha signal pathway, promote mitochondrial DNA replication and new mitochondria generation;Stabilize mitochondrial membrane potential, improve ATP synthesis efficiency;Synergistically activate mitochondrial autophagy, improve mitochondrial dysfunction and then relieve aging.

The application discloses application of a MAC-1 agonist in preparation of a medicine for treating and / or relieving cerebral hemorrhage. Specifically disclosed is the use of Leukadherin-1 (LA-1) or a pharmaceutically acceptable salt, isomer or derivative thereof in preparation of a medicine for treating cerebral hemorrhage and secondary brain injury thereof. The medicine can inhibit the migration of immune cells across the blood-brain barrier, reduce cerebral edema, promote hematoma absorption and reduce neural inflammation by regulating the MAC-1-mediated immune adhesion signal pathway, thereby exerting a neuroprotective effect. Meanwhile, a pharmaceutical composition containing the MAC-1 agonist is provided. The application provides a new target and a drug development strategy for cerebral hemorrhage treatment.

The application relates to the field of digital medical technology, and provides a drug efficacy prediction method based on artificial intelligence and related equipment.The method comprises the following steps: performing feature extraction on an original data set to obtain a first target feature set; performing analysis on a second target feature set and a third target feature set of each time node respectively to obtain an analysis result of a first signal path of the corresponding time node; and inputting the analysis result of the first signal path of each time node, the second target feature set, the third target feature set and a corresponding drug efficacy result into a pre-trained time sequence prediction model to obtain a drug efficacy prediction result of each time node.The drug efficacy at a subsequent medication time node is predicted in advance, so that doctors can more reasonably formulate a medical scheme for patients, and the working efficiency of the doctors is improved.

The application discloses application of a PI3K-gamma-delta signal path inhibitor in preparation of a product for treating central nervous system leukemia and the product, and solves the technical problem that the prior art lacks a molecular targeting product for acute lymphoblastic leukemia with CNSL which has better effect. The application comprises: application of the PI3K-gamma-delta signal path inhibitor in preparation of a product for treating acute lymphoblastic leukemia with central nervous system leukemia, and application of the PI3K-gamma-delta signal path inhibitor in preparation of a product for inhibiting proliferation, invasion and migration of acute lymphoblastic leukemia with central nervous system leukemia. The application also comprises a product of the PI3K-gamma-delta signal path inhibitor. The application discloses that central nervous system leukemia is closely related to an expression level of MSLN, and the PI3K-gamma-delta signal path inhibitor can inhibit the infiltration degree of acute lymphoblastic leukemia with central nervous system leukemia by reducing the expression level of MSLN, and prolong the survival time.

The application discloses application of papyriquinone in treatment of muscular dystrophy. The inventors find that papyriquinone can be combined with ERRa, activate ERRa and downstream signal pathways, promote muscle cell differentiation, improve muscle function, promote skeletal muscle regeneration, and finally plays a therapeutic role on Duchenne muscular dystrophy.

Current treatments for corneal disorders, also called keratopathies, depend on the stage of the keratopathy. For mild keratopathies, supportive treatments such as saline eyedrops may be sufficient to ameliorate symptoms. The present disclosure provides methods of treating corneal disorders with modulators of the WNT signaling pathway. More particularly, provided are treatments for cornea epithelial and / or endothelial injuries, defects, deficiencies, and dystrophies. Further provided are methods of dosing and pharmaceutical compositions for the treatment of corneal disorders.

The application relates to a kind of nanobodies against human HHLA2 and its application, the variable region of the nanobody includes CDR1, CDR2 and CDR3, the amino acid sequence of the CDR1 includes any one of the sequence shown in SEQ ID NO:29-36 or its mutation, the amino acid sequence of CDR2 includes any one of the sequence shown in SEQ ID NO:37-46 or its mutation, the amino acid sequence of CDR3 includes any one of the sequence shown in SEQ ID NO:47-56 or its mutation, the mutation is the replacement, insertion or deletion of 1, 2, 3 or 4 amino acids in amino acid sequence.The disclosed nanobody can be specifically combined with tumor cells expressing human HHLA2, and can improve the killing effect of immune cells on tumor cells by blocking the HHLA2 and KIR3DL3 signal pathway.

This invention belongs to the field of molecular diagnostics, specifically relating to a biomarker combination, composition, and kit for assisting in the prediction of pancreatic cancer metastasis. The invention provides a biomarker combination for assisting in the prediction of pancreatic cancer metastasis, comprising: the extracellular domain of free receptor tyrosine kinase (sAXL) and growth arrest-specific protein 6 (GAS6). Using the biomarker combination of this invention, the extracellular domain of free plasma membrane proteins in a sample can be accurately identified, thereby providing a reference for the activation status of signaling pathways and the identification of potential targets and biomarkers for disease treatment and / or prevention.

This invention relates to the field of bioactive peptide technology, and discloses a tetrapeptide with cognitive-improving function and its applications. The primary amino acid sequence of the tetrapeptide is Lys-Gly-Phe-Pro, and its molecular weight is 489.2587 Da. The tetrapeptide of this invention can be chemically synthesized or directionally prepared from sea cucumber protease hydrolysates. The tetrapeptide of this invention exhibits cognitive-improving activity, mainly through inhibiting GABA. B The expression of R activates the cAMP / PKA / CREB signaling pathway, promotes the release of the inhibitory neurotransmitter GABA, reduces oxidative stress damage, increases the gene expression of neurotrophic factors Bdnf and Nt3, and significantly upregulates the gene expression of antioxidant enzymes Sod1 and Gpx1, thereby exerting a neuroprotective effect and improving age-induced cognitive impairment.

Disclosed are a nanobody that specifically binds to LRP5 and / or LRP6 and a use thereof. The nanobody has the ability to selectively target and bind to LRP5 and / or LRP6. Some antibodies can inhibit the interaction between LRP5 and / or LRP6 and Wnt proteins, thereby effectively suppressing the Wnt signaling pathway. The provided nanobody specifically recognizes co-receptors LRP5 and / or LRP6 of the Wnt signaling pathway, exhibits high binding affinity, and can be widely applied to the field of detection and related research of LRP5 and / or LRP6.

This invention discloses the use of arginine polyesteramide in the preparation of drugs for treating dry age-related macular degeneration (AMD). This invention is the first to discover that arginine polyesteramide 2A6S can be used to prevent and treat dry age-related macular degeneration (AMD). Specifically, 2A6S can effectively restore ERG amplitude in patients with dry AMD, reduce fundus pathological damage and maintain the integrity of the retinopathy of prematurity (RPE), and reduce the expression of inflammatory factors by inhibiting the NF-κB pathway. Its efficacy is superior to existing complement C3 inhibitory peptides and NF-κB signaling pathway inhibitors, and it has potential clinical application value for dry AMD, contributing to the expansion of treatment strategies for dry AMD.

The invention discloses application of melatonin in anti-inflammatory intervention of bilirubin encephalopathy, and the melatonin relieves neuroinflammation of the bilirubin encephalopathy by inhibiting activation of NLRP3 inflammasome, reducing GSDMD splitting decomposition and reducing the levels of proinflammatory factors TNF-alpha, IL-6 and IL-1beta and depending on a PI3K / AKT signal channel; the administration dosage of the melatonin is 10-20 mg / kg of body weight; the medicine is administrated through intraperitoneal injection; the melatonin plays an anti-inflammatory role by inhibiting the activation of NLRP3 inflammasome; the melatonin plays an anti-inflammatory role by reducing splitting decomposition of the GSDMD; the medicine further comprises a pharmaceutically acceptable carrier. The invention provides a new anti-inflammatory treatment strategy except for reducing bilirubin for the bilirubin encephalopathy.